Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib.
Ontology highlight
ABSTRACT: Despite the significant advances in the treatment of multiple myeloma (MM), this disease is still considered incurable because of relapse and chemotherapy resistance, underscoring the need to seek novel therapies with different mechanisms. Anlotinib, a novel multi-targeted tyrosine kinase inhibitor (TKI), has exhibited encouraging antitumor activity in several preclinical and clinical trials, but its effect on MM has not been studied yet. In this study, we found that anlotinib exhibits encouraging cytotoxicity in MM cells, overcomes the protective effect of the bone marrow microenvironment and suppresses tumor growth in the MM mouse xenograft model. We further examined the underlying molecular mechanism and found that anlotinib provokes cell cycle arrest, induces apoptosis and inhibits mul
SUBMITTER: Cao Y
PROVIDER: S-EPMC8046985 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA